查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1744423

遺傳性痙性下身麻痺(HSP)的全球市場:藥物，重症度別，各流通管道，各地區，機會，預測，2018年～2032年

Hereditary Spastic Paraplegia (HSP) Market Assessment, By Medication, By Severity, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 242 Pages | 商品交期: 3-5個工作天內

價格

全球遺傳性痙攣性截癱 (HSP) 市場規模預計將從 2024 年的 1.159 億美元增長至 2032 年的 3.46 億美元，預測期內（2025-2032 年）的複合年增長率為 14.65%。 HSP 病例數量的增加、基因研究的進步、支持性監管措施以及研發活動投資的增加，都將推動市場的發展。此外，基因編輯平台和神經復健解決方案的進步也有望在推動市場成長方面發揮關鍵作用。

對先進診斷解決方案和基因治療的日益關注也支持了市場的成長和擴張。全基因組定序和新一代定序技術正在實現更早的治療介入並提高診斷的準確性。研究人員也正在探索基因沉默和基因替換策略，以解決HSP的根本病因。製藥公司和學術研究機構正在投資臨床前研究活動，以測試新型療法的安全性和有效性，並了解基因型-表現型相關性。

此外，世界各地的醫療保健系統正致力於提高罕見疾病和神經系統疾病的診斷效率和治療效果，從而支持市場擴張。各國政府已出台政策，以應對包括HSP在內的日益嚴重的罕見疾病威脅，並提供稅收抵免、加速審批和研究補助金來激勵製藥公司。

按本報告提供全球遺傳性痙性下身麻痺(HSP)市場相關調查，提供市場概要，以及藥物，重症度別，各流通管道，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 摘要整理

第4章 全球遺傳性痙性下身麻痺(HSP)市場預測，2018年～2032年

  • 市場規模分析與預測
  • 市場佔有率分析與預測
    • 按藥物
      • 骨骼肌鬆弛劑
      • 抗焦慮藥物
      • 苯二氮平類藥物
      • 非類固醇抗發炎藥 (NSAID)
      • 其他
    • 重症度別
      • 輕度
      • 中等度
      • 重度
    • 各流通管道
      • 醫院藥局
      • 零售藥局
      • 線上藥局
    • 各地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東·非洲
    • 各企業市場佔有率分析(前五名公司以及其他- 各金額，2024年)
  • 2024年的市場地圖分析

第5章 北美的遺傳性痙性下身麻痺(HSP)市場預測，2018年～2032年

  • 市場規模分析與預測
  • 市場佔有率分析與預測
  • 各國市場評估
    • 美國
    • 加拿大
    • 墨西哥

第6章 歐洲的遺傳性痙性下身麻痺(HSP)市場預測，2018年～2032年

  • 德國
  • 法國
  • 義大利
  • 英國
  • 俄羅斯
  • 荷蘭
  • 西班牙
  • 土耳其
  • 波蘭

第7章 亞太地區的遺傳性痙性下身麻痺(HSP)市場預測，2018年～2032年

  • 印度
  • 中國
  • 日本
  • 澳洲
  • 越南
  • 韓國
  • 印尼
  • 菲律賓

第8章 南美的遺傳性痙性下身麻痺(HSP)市場預測，2018年～2032年

  • 巴西
  • 阿根廷

第9章 中東·非洲的遺傳性痙性下身麻痺(HSP)市場預測，2018年～2032年

  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 需求供給分析

  • 供應鏈分析
  • 價值鏈分析

第11章 波特的五力分析

第12章 大環境分析

第13章 價格分析

第14章 市場動態

  • 市場促進因素
  • 市場課題

第15章 市場趨勢與發展

  • 臨床試驗
  • 新的開發與創新

第16章 案例研究

第17章 競爭情形

  • 前五名市場領導的競爭矩陣
  • 前五名參與企業的SWOT分析
  • 前10名市場主要企業的形勢
    • Novartis A.G.
    • Pfizer Inc.
    • BlackfinBio Limited
    • Sanofi S.A.
    • Elpida Therapeutics
    • Genetic Cures for Kids Inc.
    • Daiichi Sankyo Company, Limited

第18章 策略性建議

第19章 關於調查公司·免責聲明

Product Code: MX13280

Global hereditary spastic paraplegia (HSP) market is projected to witness a CAGR of 14.65% during the forecast period 2025-2032, growing from USD 115.90 million in 2024 to USD 346 million in 2032. The market's growth is supported by the rising cases of HSP, advancements in genetic research, supportive regulatory measures, and rising investments towards research and development activities. Additionally, advancements in gene editing platforms and neurorehabilitation solutions are also expected to play a significant role in driving the growth of the market.

Increasing emphasis on advanced diagnostic solutions and gene therapies is also supporting the market's growth and expansion. Whole-exome sequencing and next-generation sequencing are allowing early therapeutic interventions and improving diagnostic accuracy. Researchers are also exploring gene silencing and replacement strategies to address the underlying cause of HSP. Pharmaceutical companies and academic and research institutions are investing in preclinical research activities to test the safety and efficacy of novel therapies and understand genotype-phenotype correlations.

Moreover, healthcare systems across the globe are focusing on improving diagnostic efficiency and treatments for rare diseases and neurological disorders, supporting the market's expansion. Various governments are implementing policies to combat the growing threat of rare diseases, including HSP and providing tax credits, accelerated approvals, and research grants to incentivize pharmaceutical companies.

Increasing Regulatory Support Boosts Market Growth

Increasing support from different regulatory bodies such as the Food and Drug Administration (FDA) is accelerating the clinical evaluation and development of innovative therapeutic solutions for treating and managing neurogenetic disorders. For instance, in May 2025, BlackfinBio Limited received approval from the US FDA to begin phase 1/2 clinical trial for adeno-associated virus (AAV) gene therapy targeting HSP, Type 47. The trial aims to assess the tolerability, safety, and efficacy of the AAV gene therapy in patients with HSP, Type 47. Such approvals validate scientific advancements and incentivize pharmaceutical companies to invest in research and development activities.

Additionally, the provision of rare pediatric disease status and orphan drug designation further encourage pharmaceutical companies to pursue novel therapeutic solutions by providing benefits such as financial incentives and market exclusivity. Such supportive initiatives foster collaboration between industry leaders, clinical centers, and academic institutions, resulting in the expedition of molecular and genetic discoveries, improving treatment outcomes and bolstering the availability of treatment options, positively influencing the market's expansion.

Rising Research Activities Support Market Expansion

Advances in molecular genetics and next-generation sequencing have already identified over 80 genetic causes of HSP, laying the groundwork for variant-specific therapies. Researchers across the globe are focusing on developing gene therapies for HSP. For instance, in January 2024, a team of researchers from the Korea Research Institute of Bioscience & Biotechnology (KRIBB) developed gene therapy for HSP. The team identified the role of ARL6IP1 gene in the onset of HSP. Their findings showed that ARL6IP1 is involved in maintaining homeostasis of cellular organelles and is located in the mitochondrial associated ER membrane. The presence of a robust research environment that fosters innovations and supports development of new therapies is allowing researchers to bridge the gaps in HSP care and develop disease modifying treatments.

Hospitals Pharmacies Account for Significant Share of the Market

The segment's dominance can be attributed to the central role played by hospitals and clinics in the management and treatment of HSP. The condition requires multidisciplinary care involving physiotherapies and neurologists, among other specialists, which is only available and effectively coordinated in hospitals and clinics. Additionally, hospitals and clinics also offer medication management and comprehensive patient monitoring, which is essential for diseases such as HSP. They are equipped with the necessary technology and professionals to handle complex cases, provide patient education to improve treatment adherence, and adjust treatment regimens. Additionally, hospitals algo participate in various clinical trials to elevate the understanding of different mechanisms associated with HSP, further strengthening the segment's position. For instance, Boston Children's Hospital is conducting an observational study to better understand the role of genetic factors in HSP. The study is estimated to conclude in April 2027.

North America Holds Major Market Share

The rapid growth of the market in North America can be attributed to the availability of high fundings for rare disease research, strong presence of leading market players, availability of advanced genetic testing services, and rising incidences of HSP. As per the estimates of the Spastic Paraplegia Foundation, in the United States the HSP incidence rate is approximately 20,000.

The strong presence of leading academic and research institutions and pharmaceutical companies is supporting innovations and new product launches, driving the market's growth and expansion. In countries such as the United States, supportive framework and initiatives including the Orphan Drug Act are enabling early-stage clinical research and providing financial incentives for HSP drug development. Additionally, the rising popularity of telehealth services is improving patient access to specialists and neurologists, especially in rural locations, allowing patients to receive timely diagnosis, supporting the market's expansion.

Future Market Scenario (2025 - 2032F)

The market is expected to witness significant growth over the forecast period, due to rising awareness, technological advancements, and increasing research in curative gene therapies. With rising investments from both private and public sectors, the focus on disease-modifying treatments is increasing, bolstering the availability of therapeutic solutions that tackle the root cause of the condition and just symptomatic management. Additionally, rising emphasis on research activities to bolster the availability of new treatments for HSP is also expected to propel the market's expansion. For instance, Shanghai Sixth People's Hospital, affiliated to Shanghai Jiao Tong University School of Medicine is conducting an interventional study to explore the safety and efficacy of calcium folinate for treating patients with spastic paraplegia 56. The study is estimated to conclude in May 2030. Additionally, advancements in AI-powered diagnostic and biomarker analysis are expected to support early disease detection, providing lucrative growth opportunities for the market.

Key Players Landscape and Outlook

The leading market players are focusing on conducting clinical trials, developing new therapies, and working on improving the understanding of the genetic factors responsible for HSP. The key players are also focusing on seeking investments to support their research and development activities and bolster the availability of novel therapeutic solutions. For instance, in December 2023, BlackfinBio Limited raised approximately USD 3.7 million in seed investment to advance treatments for HSP. Such investments are expected to accelerate the translation of laboratory discoveries to therapies, improving prospects for the patient population across the globe and allowing companies to expand their presence in the industry.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Hereditary Spastic Paraplegia (HSP) Market Outlook, 2018-2032F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Medication
      • 4.2.1.1. Skeletal Muscle Relaxants
      • 4.2.1.2. Anxiolytics
      • 4.2.1.3. Benzodiazepines
      • 4.2.1.4. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
      • 4.2.1.5. Others
    • 4.2.2. By Severity
      • 4.2.2.1. Mild
      • 4.2.2.2. Moderate
      • 4.2.2.3. Severe
    • 4.2.3. By Distribution Channel
      • 4.2.3.1. Hospital Pharmacies
      • 4.2.3.2. Retail Pharmacies
      • 4.2.3.3. Online Pharmacies
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia-Pacific
      • 4.2.4.4. South America
      • 4.2.4.5. Middle East and Africa
    • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 4.3. Market Map Analysis, 2024
    • 4.3.1. By Medication
    • 4.3.2. By Severity
    • 4.3.3. By Distribution Channel
    • 4.3.4. By Region

5. North America Hereditary Spastic Paraplegia (HSP) Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Medication
      • 5.2.1.1. Skeletal Muscle Relaxants
      • 5.2.1.2. Anxiolytics
      • 5.2.1.3. Benzodiazepines
      • 5.2.1.4. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
      • 5.2.1.5. Others
    • 5.2.2. By Severity
      • 5.2.2.1. Mild
      • 5.2.2.2. Moderate
      • 5.2.2.3. Severe
    • 5.2.3. By Distribution Channel
      • 5.2.3.1. Hospital Pharmacies
      • 5.2.3.2. Retail Pharmacies
      • 5.2.3.3. Online Pharmacies
    • 5.2.4. By Country Share
      • 5.2.4.1. United States
      • 5.2.4.2. Canada
      • 5.2.4.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Hereditary Spastic Paraplegia (HSP) Market Outlook, 2018-2032F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Medication
          • 5.3.1.2.1.1. Skeletal Muscle Relaxants
          • 5.3.1.2.1.2. Anxiolytics
          • 5.3.1.2.1.3. Benzodiazepines
          • 5.3.1.2.1.4. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
          • 5.3.1.2.1.5. Others
        • 5.3.1.2.2. By Severity
          • 5.3.1.2.2.1. Mild
          • 5.3.1.2.2.2. Moderate
          • 5.3.1.2.2.3. Severe
        • 5.3.1.2.3. By Distribution Channel
          • 5.3.1.2.3.1. Hospital Pharmacies
          • 5.3.1.2.3.2. Retail Pharmacies
          • 5.3.1.2.3.3. Online Pharmacies
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Hereditary Spastic Paraplegia (HSP) Market Outlook, 2018-2032F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Turkey
  • 6.9. Poland

7. Asia-Pacific Hereditary Spastic Paraplegia (HSP) Market Outlook, 2018-2032F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Hereditary Spastic Paraplegia (HSP) Market Outlook, 2018-2032F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Hereditary Spastic Paraplegia (HSP) Market Outlook, 2018-2032F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa

10. Demand Supply Analysis

  • 10.1. Supply Chain Analysis
  • 10.2. Value Chain Analysis

11. Porter's Five Forces Analysis

12. PESTLE Analysis

13. Pricing Analysis

14. Market Dynamics

  • 14.1. Market Drivers
  • 14.2. Market Challenges

15. Market Trends and Developments

  • 15.1. Clinical Trials
  • 15.2. New Developments and Innovations

16. Case Studies

17. Competitive Landscape

  • 17.1. Competition Matrix of Top 5 Market Leaders
  • 17.2. SWOT Analysis for Top 5 Players
  • 17.3. Key Players Landscape for Top 10 Market Players
    • 17.3.1. Novartis A.G.
      • 17.3.1.1. Company Details
      • 17.3.1.2. Key Management Personnel
      • 17.3.1.3. Products and Services
      • 17.3.1.4. Financials (As Reported)
      • 17.3.1.5. Key Market Focus and Geographical Presence
      • 17.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 17.3.2. Pfizer Inc.
    • 17.3.3. BlackfinBio Limited
    • 17.3.4. Sanofi S.A.
    • 17.3.5. Elpida Therapeutics
    • 17.3.6. Genetic Cures for Kids Inc.
    • 17.3.7. Daiichi Sankyo Company, Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

18. Strategic Recommendations

19. About Us and Disclaimer

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 2. Global Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 3. Global Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 4. Global Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 5. Global Hereditary Spastic Paraplegia (HSP) Market Share (%), By Region, 2018-2032F
  • Figure 6. North America Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 7. North America Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 8. North America Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 9. North America Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 10. North America Hereditary Spastic Paraplegia (HSP) Market Share (%), By Country, 2018-2032F
  • Figure 11. United States Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 12. United States Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 13. United States Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 14. United States Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 15. Canada Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 16. Canada Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 17. Canada Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 18. Canada Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 19. Mexico Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 20. Mexico Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 21. Mexico Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 22. Mexico Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 23. Europe Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 24. Europe Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 25. Europe Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 26. Europe Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 27. Europe Hereditary Spastic Paraplegia (HSP) Market Share (%), By Country, 2018-2032F
  • Figure 28. Germany Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 29. Germany Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 30. Germany Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 31. Germany Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 32. France Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 33. France Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 34. France Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 35. France Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 36. Italy Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 37. Italy Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 38. Italy Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 39. Italy Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 40. United Kingdom Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 41. United Kingdom Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 42. United Kingdom Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 43. United Kingdom Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 44. Russia Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 45. Russia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 46. Russia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 47. Russia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 48. Netherlands Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 49. Netherlands Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 50. Netherlands Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 51. Netherlands Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 52. Spain Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 53. Spain Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 54. Spain Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 55. Spain Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 56. Turkey Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 57. Turkey Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 58. Turkey Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 59. Turkey Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 60. Poland Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 61. Poland Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 62. Poland Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 63. Poland Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. South America Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 65. South America Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 66. South America Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 67. South America Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 68. South America Hereditary Spastic Paraplegia (HSP) Market Share (%), By Country, 2018-2032F
  • Figure 69. Brazil Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 70. Brazil Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 71. Brazil Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 72. Brazil Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 73. Argentina Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 74. Argentina Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 75. Argentina Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 76. Argentina Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 77. Asia-Pacific Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 78. Asia-Pacific Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 79. Asia-Pacific Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 80. Asia-Pacific Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 81. Asia-Pacific Hereditary Spastic Paraplegia (HSP) Market Share (%), By Country, 2018-2032F
  • Figure 82. India Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 83. India Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 84. India Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 85. India Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 86. China Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 87. China Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 88. China Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 89. China Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 90. Japan Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 91. Japan Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 92. Japan Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 93. Japan Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 94. Australia Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 95. Australia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 96. Australia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 97. Australia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 98. Vietnam Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 99. Vietnam Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 100. Vietnam Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 101. Vietnam Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 102. South Korea Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 103. South Korea Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 104. South Korea Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 105. South Korea Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 106. Indonesia Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 107. Indonesia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 108. Indonesia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 109. Indonesia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 110. Philippines Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 111. Philippines Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 112. Philippines Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 113. Philippines Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 114. Middle East & Africa Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 115. Middle East & Africa Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 116. Middle East & Africa Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 117. Middle East & Africa Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 118. Middle East & Africa Hereditary Spastic Paraplegia (HSP) Market Share (%), By Country, 2018-2032F
  • Figure 119. Saudi Arabia Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 120. Saudi Arabia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 121. Saudi Arabia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 122. Saudi Arabia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 123. UAE Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 124. UAE Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 125. UAE Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 126. UAE Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 127. South Africa Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 128. South Africa Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 129. South Africa Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 130. South Africa Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 131. By Medication Map-Market Size (USD Million) & Growth Rate (%), 2024
  • Figure 132. By Severity Map-Market Size (USD Million) & Growth Rate (%), 2024
  • Figure 133. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), 2024
  • Figure 134. By Region Map-Market Size (USD Million) & Growth Rate (%), 2024